Global Macular Degeneration Drug Pipeline Market Size, Status and Forecast 2021-2027

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Gene therapy
  • 1.2.3 Small molecules
  • 1.2.4 Stem cell therapy
  • 1.2.5 Gene therapies
• 1.3 Market by Application
  • 1.3.1 Global Macular Degeneration Drug Pipeline Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Hospital
  • 1.3.3 Research Institute
  • 1.3.4 Commercial
  • 1.3.5 Other
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2016-2027)
• 2.2 Macular Degeneration Drug Pipeline Growth Trends by Regions
  • 2.2.1 Macular Degeneration Drug Pipeline Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Macular Degeneration Drug Pipeline Historic Market Share by Regions (2016-2021)
  • 2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Regions (2022-2027)
• 2.3 Macular Degeneration Drug Pipeline Industry Dynamic
  • 2.3.1 Macular Degeneration Drug Pipeline Market Trends
  • 2.3.2 Macular Degeneration Drug Pipeline Market Drivers
  • 2.3.3 Macular Degeneration Drug Pipeline Market Challenges
  • 2.3.4 Macular Degeneration Drug Pipeline Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
  • 3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2016-2021)
  • 3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2016-2021)
• 3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue
• 3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio
  • 3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2020
• 3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served
• 3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service
• 3.7 Date of Enter into Macular Degeneration Drug Pipeline Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Macular Degeneration Drug Pipeline Breakdown Data by Type

• 4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2016-2021)
• 4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2022-2027)

5 Macular Degeneration Drug Pipeline Breakdown Data by Application

• 5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2016-2021)
• 5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Macular Degeneration Drug Pipeline Market Size (2016-2027)
• 6.2 North America Macular Degeneration Drug Pipeline Market Size by Type
  • 6.2.1 North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
  • 6.2.2 North America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
  • 6.2.3 North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
• 6.3 North America Macular Degeneration Drug Pipeline Market Size by Application
  • 6.3.1 North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
  • 6.3.2 North America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
  • 6.3.3 North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
• 6.4 North America Macular Degeneration Drug Pipeline Market Size by Country
  • 6.4.1 North America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
  • 6.4.2 North America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Macular Degeneration Drug Pipeline Market Size (2016-2027)
• 7.2 Europe Macular Degeneration Drug Pipeline Market Size by Type
  • 7.2.1 Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
  • 7.2.2 Europe Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
  • 7.2.3 Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
• 7.3 Europe Macular Degeneration Drug Pipeline Market Size by Application
  • 7.3.1 Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
  • 7.3.2 Europe Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
  • 7.3.3 Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
• 7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country
  • 7.4.1 Europe Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
  • 7.4.2 Europe Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2016-2027)
• 8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type
  • 8.2.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application
  • 8.3.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region
  • 8.4.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2016-2027)
• 9.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type
  • 9.2.1 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
  • 9.2.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
  • 9.2.3 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
• 9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application
  • 9.3.1 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
  • 9.3.2 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
  • 9.3.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
• 9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country
  • 9.4.1 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
  • 9.4.2 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2016-2027)
• 10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type
  • 10.2.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application
  • 10.3.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country
  • 10.4.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Amgen
  • 11.1.1 Amgen Company Details
  • 11.1.2 Amgen Business Overview
  • 11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
  • 11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.1.5 Amgen Recent Development
• 11.2 Roche
  • 11.2.1 Roche Company Details
  • 11.2.2 Roche Business Overview
  • 11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
  • 11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.2.5 Roche Recent Development
• 11.3 Adverum Biotechnologies
  • 11.3.1 Adverum Biotechnologies Company Details
  • 11.3.2 Adverum Biotechnologies Business Overview
  • 11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
  • 11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.3.5 Adverum Biotechnologies Recent Development
• 11.4 AsclepiX Therapeutics
  • 11.4.1 AsclepiX Therapeutics Company Details
  • 11.4.2 AsclepiX Therapeutics Business Overview
  • 11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
  • 11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.4.5 AsclepiX Therapeutics Recent Development
• 11.5 Bioeq AG
  • 11.5.1 Bioeq AG Company Details
  • 11.5.2 Bioeq AG Business Overview
  • 11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
  • 11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.5.5 Bioeq AG Recent Development
• 11.6 Sinocelltech
  • 11.6.1 Sinocelltech Company Details
  • 11.6.2 Sinocelltech Business Overview
  • 11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
  • 11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.6.5 Sinocelltech Recent Development
• 11.7 RemeGen
  • 11.7.1 RemeGen Company Details
  • 11.7.2 RemeGen Business Overview
  • 11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
  • 11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.7.5 RemeGen Recent Development
• 11.8 Grifols, S.A.
  • 11.8.1 Grifols, S.A. Company Details
  • 11.8.2 Grifols, S.A. Business Overview
  • 11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
  • 11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.8.5 Grifols, S.A. Recent Development
• 11.9 Kyowa Kirin
  • 11.9.1 Kyowa Kirin Company Details
  • 11.9.2 Kyowa Kirin Business Overview
  • 11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
  • 11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.9.5 Kyowa Kirin Recent Development
• 11.10 EyePoint Pharmaceutical
  • 11.10.1 EyePoint Pharmaceutical Company Details
  • 11.10.2 EyePoint Pharmaceutical Business Overview
  • 11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
  • 11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.10.5 EyePoint Pharmaceutical Recent Development
• 11.11 IVERIC Bio
  • 11.11.1 IVERIC Bio Company Details
  • 11.11.2 IVERIC Bio Business Overview
  • 11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
  • 11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.11.5 IVERIC Bio Recent Development
• 11.12 Kodiak Sciences
  • 11.12.1 Kodiak Sciences Company Details
  • 11.12.2 Kodiak Sciences Business Overview
  • 11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
  • 11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.12.5 Kodiak Sciences Recent Development
• 11.13 Ribomic
  • 11.13.1 Ribomic Company Details
  • 11.13.2 Ribomic Business Overview
  • 11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
  • 11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.13.5 Ribomic Recent Development
• 11.14 Lineage Cell Therapeutics
  • 11.14.1 Lineage Cell Therapeutics Company Details
  • 11.14.2 Lineage Cell Therapeutics Business Overview
  • 11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
  • 11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.14.5 Lineage Cell Therapeutics Recent Development
• 11.15 Graybug Vision
  • 11.15.1 Graybug Vision Company Details
  • 11.15.2 Graybug Vision Business Overview
  • 11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
  • 11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.15.5 Graybug Vision Recent Development
• 11.16 CHABiotech
  • 11.16.1 CHABiotech Company Details
  • 11.16.2 CHABiotech Business Overview
  • 11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
  • 11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.16.5 CHABiotech Recent Development
• 11.17 Shanghai Henlius Biotech
  • 11.17.1 Shanghai Henlius Biotech Company Details
  • 11.17.2 Shanghai Henlius Biotech Business Overview
  • 11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
  • 11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.17.5 Shanghai Henlius Biotech Recent Development
• 11.18 Bio-Thera Solutions
  • 11.18.1 Bio-Thera Solutions Company Details
  • 11.18.2 Bio-Thera Solutions Business Overview
  • 11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
  • 11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.18.5 Bio-Thera Solutions Recent Development
• 11.18 Alteogen

.1 Alteogen Company Details

.2 Alteogen Business Overview

.3 Alteogen Macular Degeneration Drug Pipeline Introduction

.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)

.5 Alteogen Recent Development

• 11.20 Outlook Therapeutics
  • 11.20.1 Outlook Therapeutics Company Details
  • 11.20.2 Outlook Therapeutics Business Overview
  • 11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
  • 11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
  • 11.20.5 Outlook Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer